



## **APIM THERAPEUTICS FILES FIRST-IN-CLASS DRUG, ATX-101, FOR CLINICAL TRIAL APPROVAL**

**Trondheim, May 25<sup>th</sup>, 2018.**

APIM Therapeutics announced today that Therapim Pty Ltd, its fully owned subsidiary residing in Queensland, Australia, has submitted a formal application for clinical trial approval in Australia for the peptide drug candidate ATX-101. The application will allow Therapim to initiate a multicenter, first-in-man phase I clinical trial evaluating the safety, tolerability and pharmacokinetics of ATX-101 in a total of 36 patients with advanced solid tumors.

ATX-101 is a first-in-class peptide drug targeting a novel therapeutic intervention point shown to be critical in the regulation of cellular responses to stress and in tumor evasion from therapy. Briefly, ATX-101 blocks protein-protein interactions between the master cell regulator PCNA (Proliferating Cell Nuclear Antigen) and a set of stress-related proteins containing a specific 5-amino acid PCNA-binding motif. Targeting this mechanism resulted in significant potentiation of the activity of a plethora of anti-cancer drugs in several preclinical blood and solid tumor cancer models.

“We are extremely pleased to have reached this significant milestone as we continue to advance with the development of our novel therapeutic intervention point in cancer patients,” stated Kostas Alevizopoulos, CEO of APIM Therapeutics. “We believe that ATX-101 could be a promising new candidate to test in clinical trials”.

Erlend Skagseth, Chairman of APIM Therapeutics and Managing Partner at Sarsia Seed (Lead investor), stated: “Filing this clinical trial application marks a significant milestone for APIM Therapeutics. We are excited to be part of this development program aiming to provide new therapeutic options to cancer patients”.

Based on current projections, the initial dosing of ATX-101 is expected to begin in late Q3 2018 with a target trial conclusion date estimated for late 2019 / early 2020.

### **About APIM Therapeutics**

APIM Therapeutics is an early stage therapeutic company based on ground breaking research by Prof. Marit Otterlei and co-workers (Norwegian University of Science and Technology, NTNU, Trondheim, Norway). The company operates since 2009 and is financially backed up by an investor syndicate comprising, among others, Sarsia Seed, NIK III, Bergens Forskningsstiftelse and Investinor. The latest company transaction was concluded in Dec. 2017 (NOK 25M).

For further information, please contact:

APIM Therapeutics A/S  
Kostas Alevizopoulos, CEO  
Tel: +47 73 49 4002  
e-mail: [kalevizo@apimtherapeutics.com](mailto:kalevizo@apimtherapeutics.com)  
[www.apimtherapeutics.com](http://www.apimtherapeutics.com)